Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06760156 · ClinicalTrials.gov registry record · Phase 2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
A Phase 2 study of Large B-cell Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06760156: Recruiting Phase 2 study of Large B-cell Lymphoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT06760156 is a Phase 2 study of Large B-cell Lymphoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 28 participants, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06760156, a Phase 2 study of Large B-cell Lymphoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Primary Outcome
Complete Response Rate (CRR) is defined as the proportion of patients with a Complete Response (CR)
Conditions Studied
Interventions
- DRUG Lenalidomide
- DRUG Tafasitamab
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-03-19 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What NCT06760156 shows while recruiting
NCT06760156 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 158-participant average among 28 other Large B-cell Lymphoma trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Large B-cell Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT06760156 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06760156 about?
NCT06760156 is a clinical study titled "Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym". The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
What is the current status of trial NCT06760156?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-03-19. Estimated completion is 2028-01.
What conditions does trial NCT06760156 study?
This clinical trial studies the following conditions: Large B-cell Lymphoma.
What interventions are being tested in trial NCT06760156?
The interventions under investigation include: Lenalidomide (DRUG), Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT06760156?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06760156 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06760156's enrollment target sits among peer trials
28 19th of 28 higher than 9 of 28 other Large B-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Large B-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
CAR-T Followed by Bispecific Antibodies
RECRUITING · Phase 2
-
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RECRUITING · Phase 2
-
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI